Security Snapshot

Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) Institutional Ownership

CUSIP: 004890109

13F Institutional Holders and Ownership History from Q4 2022 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

48

Shares (Excl. Options)

18,610,735

Price

$2.41

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
ACRV on Nasdaq
Shares outstanding
38,870,454
Price per share
$1.29
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
18,610,735
Total reported value
$44,851,327
% of total 13F portfolios
0%
Share change
+1,150,121
Value change
+$2,807,440
Number of holders
48
Price from insider filings
$1.29
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 004890109.
  • 48 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 45 to 48 between Q3 2025 and Q4 2025.
  • Reported value moved from $31,603,874 to $44,851,327.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 48 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 22% $12,594,027 8,396,018 RA Capital Management, L.P. 19 Mar 2026
Sands Capital Life Sciences Pulse Fund II, L.P. 6.8% $2,525,900 2,122,605 Sands Capital Life Sciences Pulse Fund II, L.P. 30 Jun 2025
CITADEL ADVISORS LLC 5.5% +12% $3,116,579 +$326,709 1,721,867 +12% Kenneth Griffin 14 Nov 2025

As of 31 Dec 2025, 48 institutional investors reported holding 18,610,735 shares of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV). This represents 48% of the company’s total 38,870,454 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 21% 8,340,508 0% 0.21% $20,100,624
Sands Capital Alternatives, LLC 5.5% 2,122,605 0% 0.99% $5,115,478
CITADEL ADVISORS LLC 4.2% 1,641,884 +6.5% 0% $3,956,941
WELLINGTON MANAGEMENT GROUP LLP 2.3% 888,130 0% 0% $2,140,393
VANGUARD GROUP INC 1.8% 698,857 +12% 0% $1,684,246
RENAISSANCE TECHNOLOGIES LLC 1.6% 634,169 +1.7% 0% $1,528,347
TWO SIGMA INVESTMENTS, LP 1.5% 585,069 +83% 0% $1,410,016
ACADIAN ASSET MANAGEMENT LLC 1.5% 581,208 +532% 0% $1,400,000
MARSHALL WACE, LLP 1.3% 496,081 +231% 0% $1,195,556
ACORN CAPITAL ADVISORS, LLC 1% 405,237 0% 0.33% $976,622
UBS Group AG 0.9% 348,541 -49% 0% $839,984
JANE STREET GROUP, LLC 0.88% 342,071 +18% 0% $824,391
TWO SIGMA ADVISERS, LP 0.86% 333,773 +145% 0% $804,393
BlackRock, Inc. 0.53% 205,124 -38% 0% $494,349
GEODE CAPITAL MANAGEMENT, LLC 0.51% 198,223 +3.2% 0% $477,891
MILLENNIUM MANAGEMENT LLC 0.31% 121,524 -34% 0% $292,873
GOLDMAN SACHS GROUP INC 0.31% 119,422 +505% 0% $287,807
STATE STREET CORP 0.17% 67,145 0% 0% $161,819
NORTHERN TRUST CORP 0.16% 63,718 +51% 0% $153,561
PRELUDE CAPITAL MANAGEMENT, LLC 0.12% 48,015 0.01% $115,716
MORGAN STANLEY 0.12% 46,831 -18% 0% $112,863
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.11% 42,900 +87% 0% $103,389
Squarepoint Ops LLC 0.07% 26,162 -75% 0% $63,050
BARCLAYS PLC 0.06% 24,402 +22% 0% $58,809
BAKER BROS. ADVISORS LP 0.06% 22,809 0% 0% $54,970

Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 18,610,735 $44,851,327 +$2,807,440 $2.41 48
2025 Q3 17,461,169 $31,603,874 -$171,329 $1.81 45
2025 Q2 17,802,633 $21,184,501 -$10,332,852 $1.19 52
2025 Q1 22,517,048 $45,710,668 -$2,113,900 $2.03 60
2024 Q4 23,250,351 $139,966,100 -$971,335 $6.02 60
2024 Q3 22,960,755 $160,726,039 -$2,679,680 $7.00 51
2024 Q2 23,451,873 $136,019,583 +$47,352,617 $5.80 51
2024 Q1 15,245,438 $109,005,559 +$3,386,877 $7.15 45
2023 Q4 14,865,624 $73,138,289 +$986,082 $4.92 40
2023 Q3 15,093,861 $144,297,342 -$326,020 $9.56 43
2023 Q2 15,126,531 $196,038,750 -$1,147,208 $12.96 40
2023 Q1 15,216,182 $191,059,725 +$6,824,894 $12.69 39
2022 Q4 14,965,637 $170,360,092 +$170,360,092 $11.52 18